In some children with acute myeloid leukemia, cancer cells have the same amount of DNA changes as healthy blood stem cells. Researchers were surprised to find these children have a poorer chance of survival compared to children whose leukemia has an above-average number of DNA changes. Their new study offers insight into how this form of blood cancer can develop in children. In the future, the new findings may help identify which patients have a high-risk form of the disease.
Cancer is caused by mistakes in a cell's DNA; the longer we live, the greater the chance of such changes. The number of DNA faults gradually adds up as we get older. But children's cells have relatively few DNA changes – so it is still unclear why children can develop cancer.
In a new study, scientists from the Princess Máxima Center for pediatric oncology looked at the development of acute myeloid leukemia (AML) in children. Some 25 children are diagnosed each year, and in around a quarter of the children the disease comes back after treatment. Better understanding of the causes and underlying biology is needed to improve treatment.
Many more DNA faults
To find out what goes wrong in the DNA of the cancer cells in children, the researchers compared the complete DNA of healthy blood stem cells with that of leukemia cells. They did this with biopsies from the bone marrow of children treated for AML in the Máxima, and internationally available data from 90 children with AML. Their study was published on Thursday 5 August in the journal Blood Cancer Discovery.
We saw that in some children, the amount and types of DNA changes in leukemia cells was very different from what we see in healthy blood stem cells."
Dr. Ruben van Boxtel, Principal Investigator, Princess Máxima Center
The leukemia cells in these children had many more DNA faults compared to healthy blood stem cells. This increase was due to oxidation, a kind of 'rusting' of the DNA that causes damage.
Better chance of survival
The children in this group had a better chance of survival compared to children who had the same number of DNA changes in the leukemia and healthy blood stem cells. 'That was surprising,' says Dr Ruben van Boxtel, who is also an Oncode Investigator. 'DNA changes are what make cancer malignant. With more of these changes, you would expect a worse outcome.' When the team looked into more detail, they found that in these children, AML probably started in more specialized blood cells that are less likely to become malignant.
In the future, the amount of DNA faults in blood stem cells could help identify high- or low-risk forms of AML in children, Van Boxtel hopes. 'Instead of looking for specific DNA changes, we would then only need to measure the amount and type of DNA damage in the blood stem cells. That is a very easy test, for which we don't need to draw extra blood.' A lot of further research is still needed, but this is the beginning, he explains. 'We are an important step closer to understanding of the origin of AML in children.'
Brandsma, A.M., et al. (2021) Mutation Signatures of Pediatric Acute Myeloid Leukemia and Normal Blood Progenitors Associated with Differential Patient Outcomes. Blood Cancer Discovery. doi.org/10.1158/2643-3230.BCD-21-0010.